SCHEMBL1406549

SCHEMBL1406549

Cc1ccc(-c2cc(C(O)C#Cc3ccc(C(=O)O)cc3)cc(C(C)(C)C)c2N(C)Cc2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.36
EGFR P00533 1/20 0.36
CSF1R P07333 1/20 0.36
PTGES O14684 3/20 0.35
ALOX5 P09917 3/20 0.35
MAP4K4 O95819 1/20 0.35
RARB P10826 5/20 0.35
RARG P13631 5/20 0.35
RARA P10276 4/20 0.35
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406441 0.93 RARB (0.42) EGFRPTGESALOX5RARBRARG
SCHEMBL1406372 0.88 MAP4K4 (0.36) MAP4K4RARBRARGRARARXRA
SCHEMBL1406320 0.83 RXRA (0.41) MAP4K4RXRARXRBMRGPRX4
SCHEMBL1406849 0.83 VCP (0.37) EGFRMAP4K4RARBRARGRARA
SCHEMBL1406969 0.81 MEN1 (0.38) RARBRARGRARARXRARXRB
SCHEMBL1406603 0.81 RARB (0.48) PTGESALOX5RARBRARGRARA
SCHEMBL1406661 0.81 RARB (0.44) PTGESALOX5RARBRARGRARA
SCHEMBL1406937 0.81 RBP4 (0.38) PTGESALOX5RARBRARGRXRA
SCHEMBL6419793 0.80 PTGES (0.32) PTGESALOX5RARBRARG
SCHEMBL6424171 0.80 PTGES (0.34) PTGESALOX5RARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG TAS2R14 1015/4885EGFR 181/4885CSF1R 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.